the Integrated Traditional Chinese and Western Medicine Treat Early Stage DKD

• Status: Recruiting
• Trial end date: 2021-09-08
• Target enrollment: 0
• Participant gender: All

Summary

Efficacy and Safety of treatment with Traditional Chinese Medicine HuangQi Decoctions in Patients with early stage of Diabetic Kidney Disease.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai University of Traditional Chinese Medicine
• Collaborator: Shanghai Jiao Tong University Affiliated Sixth People's Hospital

Criteria

Inclusion Criteria:

1. Identify the diagnosis of type 2 diabetes;

2. It meets the medical history of diabetic kidney disease, according to the Mogensen diagnostic staging standard DKD III;

3. Age 18-75 years old, gender ＆ethnicity are not limited;

4. glycated hemoglobin ≤ 10%;

5. Blood pressure is controlled below 130/80mmHg

Exclusion Criteria:

1. Combine other ACEI and ARB application indications other than hypertension;

2. Combine severe primary diseases related to heart, brain, liver and hematopoietic system;

3. Patients who have acute metabolic disorders such as diabetic ketoacidosis occur in the past month;

4. Patients who HBV serological indicators except HbsAb are positive and persistent liver function test transaminase abnormalities;

5. Patients with malignant tumors or history of malignant tumors, history of HIV infection, history of psychosis, acute central nervous system diseases, severe gastrointestinal diseases, and banned use of immunosuppressive agents;

6. Patients with acute renal failure, combined with urinary tract infection, menstrual period, intense exercise, cold and other stress states;

7. pregnant or lactating women;

8. Patients who accepted other clinical trial studies on going ;

9. Patients who combined with serious diseases and dysfunctions in other organs.